Abstract:2531 Background: TST005 is a novel bi-functional fusion protein combining a high affinity PD-L1 mAb and a differentiated TGF-β trap with improved stability. In pre-clinical study, TST005 showed no antibody-dependent dependent cytotoxicity (ADCC) or complement dependent cytotoxicity (CDC) activity. Methods: This is a Phase 1, dose escalation study with classic 3+3 design to evaluate the safety, tolerability, PK and pharmacodynamic and preliminary anti-tumor activity of TST005 and determine the maximum tolerated dose and/or the Recommended Phase 2 Dose (RP2D). Eligible solid tumor patients who have failed prior standard therapy(ies) and have received no more than one prior immune checkpoint inhibitor (ICI) treatment will be enrolled to receive TST005 intravenous (IV) infusion every 3 weeks until disease progression assessed by the Investigator per RECIST v1.1 and/or immune RECIST, or unacceptable toxicity. Results: The study is ongoing at 4 clinical centers in US and China. As of 31 Jan 2023, 18 eligible subjects have been enrolled into different TST005 dose levels: 2 at dose of 1mg/kg, 4 at 3 mg/kg, 4 at 10 mg/kg, 3 at 20 mg/kg, and 5 at the last dose level of 30 mg/kg. The enrollment is still ongoing. No DLT was observed so far. The most common treatment-emergent adverse events (TEAEs) ( > 10%) included: fatigue (38.9%), rash (22.2%), anemia (16.7%), myalgia (16.7%), and arthralgia, dehydration diarrhea, dry skin, hematuria, hypokalemia, pruritus, lymphocyte count decreased were 11.1%. 7 patients (38.9%) experienced ≥Grade 3 (G3) TEAEs according to CTCAE V5.0, 1 of whom were considered as related to TST005: it was an infusion related reaction (G3), and caused discontinuation of treatment. Two subjects experienced IRRs (G2 and G3 respectively), both at the dose of 3mg/kg cohort. One subject of 30mg/kg dose cohort presented a squamous cell carcinoma of skin, which is known as a classic side effect of TGF-β directed therapies. The subject was discontinued from study and to receive resection. No treatment-related deaths occurred. TST005 demonstrated a nonlinear PK profile between 1 to 20 mg/kg with calculated t1/2 of 4-9 days. ADA was observed in most ADA evaluable subjects, PK at doses ≥ 10mg/kg were not impacted by ADA. At 20mg/kg, the receptor occupancy increased to > 90% immediately after infusion and remain at this level up to C2D1. Start from 1mg/kg, serum TGF-β1 was depleted immediately after dosing, sustained to next dose of TST005. 11 subjects had at least one post treatment tumor assessment per RECIST 1.1. 7 subjects (63.6%) had best overall response of SD. No PR or CR had been observed. Conclusions: TST005 monotherapy demonstrated a good safety and tolerability, nonlinear PK characteristics and significant target engagement in patients with advanced solid tumors. Continue investigation of TST005 as monotherapy or in combination with other therapies are warranted. Clinical trial information: NCT04958434 .

A phase I study of TST001, a high affinity humanized anti-CLDN18.2 monoclonal antibody, in combination with capecitabine and oxaliplatin (CAPOX) as a first-line treatment of advanced G/GEJ cancer.

First-line Osemitamab (TST001) Plus Nivolumab and Capox for Advanced G/gej Cancer (transtar102): Results of Cohort G from a Phase I/IIa Study.

First-line TST001 plus capecitabine and oxaliplatin (CAPOX) for advanced G/GEJ cancer with CLDN18.2 positive overall survival data from study transtar102-Cohort C

Osemitamab in combination with capecitabine and oxaliplatin (CAPOX) as a first line treatment of advanced G/GEJ cancer: Updated data of cohort C from a phase I/IIa, multi-center study (TranStar102/TST001-1002).

PD-7 Osemitamab Plus Capecitabine and Oxaliplatin (CAPOX) As the First-Line Treatment of Advanced G/GEJ Cancer – Updated Efficacy Data Per Claudin 18.2 Expression Level from Study TranStar102/TST001-1002-cohort C

A phase Ib/II study of ASKB589 (anti-Claudin 18.2 [CLDN18.2] monoclonal antibody) combined with CAPOX and PD-1 inhibitor as first-line treatment for locally advanced, relapsed and metastatic gastric/gastro-esophageal junction (G/GEJ) adenocarcinoma.

A Multicenter, Phase 1 Study of AB011, a Recombinant Humanized Anti-Cldn18.2 Monoclonal Antibody, As Monotherapy and Combined with Capecitabine and Oxaliplatin (CAPOX) in Patients with Advanced Solid Tumors.

A Phase 1, First-in-human, Open-Label, Dose Escalation and Dose Expansion Study of TST005 in Patients with Locally Advanced or Metastatic Solid Tumors

Anti-PD-1 Antibody HX008 Combined with Oxaliplatin Plus Capecitabine for Advanced Gastric or Esophagogastric Junction Cancer: a Multicenter, Single-Arm, Open-Label, Phase Ib Trial

Tislelizumab in Combination with Chemotherapy in Chinese Patients with Advanced Gastric or Gastroesophageal Junction (G/GEJ) Cancer: Results from One Cohort of an Ongoing Phase 2 Study.

A Phase 1 Trial of Claudin 18.2-Specific Antibody-Drug Conjugate CMG901 in Patients with Advanced Gastric/gastroesophageal Junction Cancer.

Safety, Tolerability, and Preliminary Efficacy Results in Patients with Advanced Gastric/gastroesophageal Junction Adenocarcinoma from a Phase Ib/II Study of CLDN18.2 CAR T-cell Therapy (CT041).

Safety and Efficacy Results from the Phase I/IIa Study of FG-M108 Plus CAPOX As First-Line (1L) Treatment for Patients with CLDN18.2+/HER2- Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction (G/GEJ) Adenocarcinoma.

A Phase 1a Dose-Escalation, Multicenter Trial of Anti-Claudin 18.2 Antibody Drug Conjugate CMG901 in Patients with Resistant/refractory Solid Tumors.

Claudin18.2-targeted Chimeric Antigen Receptor T Cell-Therapy for Patients with Gastrointestinal Cancers: Final Results of CT041-CG4006 Phase 1 Trial.

An Open-Label, Multicenter, Phase I Study of ATG-022 in Patients with Advanced/metastatic Solid Tumors (CLINCH).

Claudin18.2-specific CAR T cells in gastrointestinal cancers: phase 1 trial final results

Preliminary Results of a Phase 1/2, First-in-human, Open-Label, Dose Escalation Study of ZL-1211 (Anti-Claudin 18.2 Mab) in Patients with Unresectable or Metastatic Solid Tumors

Phase I Trial Of Claudin 18.2-Specific Chimeric Antigen Receptor T Cells For Advanced Gastric And Pancreatic Adenocarcinoma.

Sintilimab Plus Oxaliplatin/capecitabine (capeox) As Neoadjuvant Therapy in Patients with Locally Advanced, Resectable Gastric (g)/esophagogastric Junction (GEJ) Adenocarcinoma.

195Tip GLOW: Phase III Study of First-Line Zolbetuximab + CAPOX Versus Placebo + CAPOX in Claudin18.2⁺/HER2⁻ Advanced/metastatic Gastric or Gastroesophageal Junction Adenocarcinoma (G/GEJ)